Integrum AB (publ) (INTEG-B.ST)
SEK 18.65
(3.04%)
SEK 18.65
(3.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -10.47 Million SEK | 69.19% |
| 2022 | -34 Million SEK | 54.52% |
| 2021 | -74.76 Million SEK | -942.39% |
| 2020 | -7.17 Million SEK | 41.88% |
| 2019 | -12.34 Million SEK | -33.92% |
| 2018 | -9.21 Million SEK | 20.15% |
| 2017 | -11.53 Million SEK | -230.47% |
| 2016 | -3.49 Million SEK | -205.81% |
| 2015 | 3.3 Million SEK | 467.01% |
| 2014 | 582 Thousand SEK | 152.05% |
| 2013 | -1.11 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -40.14 Million SEK | -283.15% |
| 2023 FY | -10.47 Million SEK | 69.19% |
| 2023 Q1 | -22.31 Million SEK | 34.37% |
| 2023 Q4 | -10.47 Million SEK | 51.39% |
| 2023 Q3 | -21.55 Million SEK | 17.54% |
| 2023 Q2 | -26.13 Million SEK | -17.11% |
| 2022 Q2 | -53.33 Million SEK | 6.18% |
| 2022 Q4 | -34 Million SEK | 26.54% |
| 2022 FY | -34 Million SEK | 54.52% |
| 2022 Q1 | -56.85 Million SEK | 23.96% |
| 2022 Q3 | -46.29 Million SEK | 13.21% |
| 2021 Q3 | -93.04 Million SEK | 15.09% |
| 2021 Q2 | -109.57 Million SEK | 4.92% |
| 2021 Q1 | -115.24 Million SEK | -1506.81% |
| 2021 FY | -74.76 Million SEK | -942.39% |
| 2021 Q4 | -74.76 Million SEK | 19.65% |
| 2020 Q3 | -8.84 Million SEK | -2.99% |
| 2020 FY | -7.17 Million SEK | 41.88% |
| 2020 Q4 | -7.17 Million SEK | 18.89% |
| 2020 Q2 | -8.58 Million SEK | 36.24% |
| 2020 Q1 | -13.46 Million SEK | -9.11% |
| 2019 Q4 | -12.34 Million SEK | -50.9% |
| 2019 FY | -12.34 Million SEK | -33.92% |
| 2019 Q1 | -11.89 Million SEK | -29.09% |
| 2019 Q2 | -7.46 Million SEK | 37.25% |
| 2019 Q3 | -8.17 Million SEK | -9.55% |
| 2018 Q4 | -9.21 Million SEK | 43.31% |
| 2018 FY | -9.21 Million SEK | 20.15% |
| 2018 Q1 | -4.14 Million SEK | 64.04% |
| 2018 Q2 | -25.98 Million SEK | -526.21% |
| 2018 Q3 | -16.25 Million SEK | 37.45% |
| 2017 FY | -11.53 Million SEK | -230.47% |
| 2017 Q2 | -24.03 Million SEK | -3.67% |
| 2017 Q1 | -23.18 Million SEK | -563.86% |
| 2017 Q3 | -16.96 Million SEK | 29.4% |
| 2017 Q4 | -11.53 Million SEK | 31.98% |
| 2016 Q4 | -3.49 Million SEK | 52.92% |
| 2016 Q3 | -7.41 Million SEK | 0.0% |
| 2016 Q1 | 864.67 Thousand SEK | -73.8% |
| 2016 FY | -3.49 Million SEK | -205.81% |
| 2015 FY | 3.3 Million SEK | 467.01% |
| 2015 Q4 | 3.3 Million SEK | 0.0% |
| 2014 FY | 582 Thousand SEK | 152.05% |
| 2013 FY | -1.11 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 70.194% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 100.854% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 100.854% |
| Arcoma AB | -1.12 Million SEK | -828.771% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 109.534% |
| BICO Group AB (publ) | 927.9 Million SEK | 101.129% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 108.134% |
| CellaVision AB (publ) | -56.94 Million SEK | 81.601% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 29.579% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -23.906% |
| C-Rad AB (publ) | -127.6 Million SEK | 91.79% |
| Duearity AB (publ) | 10.23 Million SEK | 202.4% |
| Dignitana AB (publ) | 13.07 Million SEK | 180.114% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 80.12% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.194% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 70.112% |
| Iconovo AB (publ) | -10.75 Million SEK | 2.592% |
| Luxbright AB (publ) | -13.83 Million SEK | 24.267% |
| Mentice AB (publ) | -49.56 Million SEK | 78.863% |
| OssDsign AB (publ) | -162.78 Million SEK | 93.564% |
| Paxman AB (publ) | -11.41 Million SEK | 8.189% |
| Promimic AB (publ) | -50.32 Million SEK | 79.181% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 154.937% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 61.658% |
| ScandiDos AB (publ) | -1.53 Million SEK | -584.294% |
| Sectra AB (publ) | -772.85 Million SEK | 98.644% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 95.382% |
| Senzime AB (publ) | -139.54 Million SEK | 92.492% |
| SpectraCure AB (publ) | -50.23 Million SEK | 79.145% |
| Stille AB | -178.5 Million SEK | 94.131% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 100.853% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 95.119% |